COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00388687
Recruitment Status : Unknown
Verified October 2006 by Medical University of Vienna.
Recruitment status was:  Recruiting
First Posted : October 17, 2006
Last Update Posted : October 17, 2006
Information provided by:
Medical University of Vienna

Brief Summary:
The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.

Condition or disease Intervention/treatment
Uterine Cervical Neoplasms Drug: 18F Fluoroazomycin Arabinoside (FAZA)

Show Show detailed description

Layout table for study information
Study Type : Observational
Enrollment : 25 participants
Observational Model: Defined Population
Time Perspective: Prospective
Official Title: Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer
Study Start Date : July 2006
Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
  • Treatment intention for the purpose of achieving cure
  • Age < 80 years
  • No previous standard or radical hysterectomy

Exclusion Criteria:

  • Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00388687

Layout table for location contacts
Contact: Matthias Schuetz, M.D. 00431404005550
Contact: Barbara Bachtiary, Prof. M.D 00431404007676

Layout table for location information
Medical Universitiy of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676   
Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676   
Principal Investigator: Georgios Karanikas, Prof. M.D.         
Sponsors and Collaborators
Medical University of Vienna
Layout table for investigator information
Study Director: Georgios Karanikas, Prof. M.D. Medical Universitiy of Vienna
Layout table for additonal information Identifier: NCT00388687    
Other Study ID Numbers: EK Nr: 241/2006
First Posted: October 17, 2006    Key Record Dates
Last Update Posted: October 17, 2006
Last Verified: October 2006
Keywords provided by Medical University of Vienna:
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Signs and Symptoms, Respiratory
Fluoroazomycin arabinoside
Molecular Mechanisms of Pharmacological Action